Article Information
History
- December 16, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Nelson Lee1,
- Lena Nguyen2,
- Sharifa Nasreen3,
- Peter C. Austin2,4,
- Kevin A. Brown1,2,5,
- Sarah A Buchan1,2,5,6,
- Ramandip Grewal1,2,6,
- Kevin L Schwartz1,2,5,
- Mina Tadrous2,7,8,
- Kumanan Wilson10,11,12,
- Sarah E Wilson1,2,5,6,
- Jeffrey C Kwong1,2,5,6,13,14,* and
- the Canadian Immunization Research Network (CIRN) investigators
- 1Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
- 2ICES, Toronto, Ontario, Canada
- 3State University of New York, Brooklyn, New York, USA
- 4Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
- 5Public Health Ontario, Toronto, Ontario, Canada
- 6Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, Ontario, Canada
- 7Women’s College Hospital, Toronto, ON, Canada
- 8Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
- 10Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
- 11Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- 12Bruyère Research Institute, Ottawa, Ontario, Canada
- 13Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada
- 14University Health Network, Toronto, Ontario, Canada
- ↵*Correspondence to: Jeffrey C Kwong Senior Scientist, ICES V1 06, 2075 Bayview Avenue, Toronto, Ontario, Canada, M4N 3M5 jeff.kwong{at}utoronto.ca (or @DrJeffKwong on Twitter)
Posted December 16, 2024.
Limited durability of protection conferred by XBB.1.5 vaccines against Omicron-associated severe outcomes among community-dwelling adults aged ≥50 years, Ontario, Canada, September 2023 to June 2024
